Daniel Catenacci Sonny Rollins' Spiritual Son These survey studies are important but a 16% difference is tough to 'swallow'
pubmed.ncbi.nlm.nih.gov/29947418/

It doesn't seem too far fetched to think the story will unfold similarly to rectal cancer

twitter.com/KrishanJethwa/…

We are not quite there yet in EsoCa- further study needed

A five-year review of #chemoradiotherapy practice in #analcancer 👉 #Radiotherapy ☢️audit results from a cancer centre in Wales, UK🇬🇧 🏥

🔗journals.sagepub.com/share/QBNZPWIH…

Pierfrancesco Franco Edward Christopher "Chris" Dee, MD #RadOnc

Results of this randomized clinical trial suggest that after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma, radiotherapy alone was noninferior to chemoradiotherapy in terms of 3-year progression-free survival. ja.ma/3UmwvuH

📋 PD-1 inhibitors with chemoradiotherapy may benefit esophageal tumor vascular normalization, alleviate hypoxia, boost radiosensitivity, and improve local control for patients.

👉 Learn how the treatment can aid patients with #esophagealcancer : buff.ly/48zEqIV

🔝 #HighlyCitedPaper
Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer
brnw.ch/21wJ77B
#cervicalcancer #chemoradiotherapy #biomarker

Pembrolizumab or placebo with chemoradiotherapy
followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

thelancet.com/journals/lance…

Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial jamanetwork.com/journals/jamao…

🎥 Dr Laure-Anne Teuwen breaks down the KEYNOTE-A18 study at #SGO2024 , highlighting the benefits of pembrolizumab + chemoradiotherapy in advanced cervical cancer. 🔥 👀 See the full discussion: bit.ly/4aZtmqi #CervicalCancer #CancerTreatment

Comparison of neoadjuvant chemotherapy (nCT) vs. chemoradiotherapy (nCRT) in esophageal cancer: pCR favored nCRT, but higher 30-d mortality. More RCTs needed for clarity.
pubmed.ncbi.nlm.nih.gov/38617451/

#dcvax $nwbo #gbm

Another phase 3 trial failure for Keytruda..

In the randomised, double-blind, phase 3 KEYNOTE-412 trial:

'Pembrolizumab plus chemoradiotherapy did not significantly improve event-free survival compared with chemoradiotherapy alone in a molecularly

Patients with stage III unresectable NSCLC who received durvalumab consolidation after chemoradiotherapy had better outcomes than those who did not receive durvalumab, supporting continued use of durvalumab as the standard of care. ja.ma/3Qe18jx

Small progress in a very nasty cancer -
Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma Mohamedtaki A. Tejani Ahmed Zakari jamanetwork.com/journals/jamao…

Does adding pembrolizumab to chemoradiotherapy improve survival in patients with locally advanced cervical cancer?

jwat.ch/3W3BIIY

#CervicalCancer

BUB1 inhibition sensitizes lung cancer cell lines to radiotherapy and chemoradiotherapy biorxiv.org/cgi/content/sh… #biorxiv_cancer

💡 KEYNOTE-A18
✅ Pembrolizumab + CRT in LACC
✅ mPFS NR in pembrolizumab group

✅ 24m PFS: 68% vs 57%
🔺 Pembrolizumab + CRT led to a 30% reduction in DR
🔺Os at 24m: 87% vs 81%

🟠 Grade 3 or higher AE: 75% vs 69%

OncoAlert
OncoDaily

📄 thelancet.com/journals/lance…

Case Study: Neoadjuvant chemoradiotherapy for laryngeal synovial sarcoma

Learn more ➡️ bit.ly/3Jns6kM

#RadOncEd #BrainCancer #HeadAndNeckCancer #OHANCAW #CancerAwareness #SynovialCellSarcoma

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial - The Lancet Oncology thelancet.com/journals/lanon…

BUB1 inhibition sensitizes lung cancer cell lines to radiotherapy and chemoradiotherapy biorxiv.org/cgi/content/sh… #bioRxiv

🎯KEYNOTE-412

Pembrolizumab plus chemoradiotherapy did not significantly improve event-free survival compared with chemoradiotherapy alone in a molecularly unselected, locally advanced HNSCC population. The Lancet Oncology #Oncology #hnscc

We used a combination of conventional pathology techniques supplemented with bulk sequencing and proteomics to assess the tumour bed in patients with a pathological complete response (pCR) to preoperative chemotherapy (nCT) and chemoradiotherapy (nCRT). 2/12